Hi Mate, thanks for sharing. I think that was a very well written stock article & analysis, backed up by rationale. The author also disclosed he was accumulating PIQ shares.
The other thing is FDA application for approval of PromarkerD in the USA, which as far as we were aware was being submitted in July 2020. The CE Mark Approval in Europe & the ~3000 patient Janssen trial CANVAS - (completed, now in a second Phase) should put us in good standing, plus the overwhelming clinic need.
Some recent news/guidelines below in relation to DKD screening & SGLT2 use, cardiology & nephrology (USA):
https://www.ajmc.com/view/new-renal-hf-results-seen-in-2020-acc-pathway-on-cv-risk-reduction
https://www.ajmc.com/view/national-kidney-foundation-ncqa-announce-measure-to-boost-testing-in-patients-with-diabetes
Our Janssen collaboration was in the CANVAS study, which included Diabetic patients with cardiovascular disease.
GLTAH
Ann: PromarkerD Intellectual Property portfolio expands, page-35
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
32.5¢ |
Change
-0.015(4.41%) |
Mkt cap ! $53.14M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.0¢ | 32.5¢ | $75.67K | 227.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9093 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 2200 | 1 |
View Market Depth
| Last trade - 15.02pm 24/06/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |